Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
February 12, 2025
A Revolution in Immunology: Creating New Possibilities with Oral Medicines
Arsalan Shabbir, MD, PhD, Vice President, Clinical Development
June 11, 2025
Powering Possibility Through Oral Medicines with Biologics-like Profiles
Nello Mainolfi, PhD, Founder, President and CEO
April 24, 2025
A New Era of Possibility: Addressing Coveted Undrugged Targets
Juliet Williams, PhD, Head of Research
Showing 41 news results
December 6, 2021
Timmerman Report: Targeted Small Molecule Protein Degraders, Nello Mainolfi on the Long Run
Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of reach for small molecules. Nello Mainolfi, PhD, Founder, President & CEO shares more about Kymera’s work and mission.
Featured Presentations & Publications
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.